Tonix Pharma secures rights to three COVID-19 vaccine candidates

Tonix Pharmaceuticals (TNXP +4.7%) inks an agreement with the University of Alberta for exclusive rights to three COVID-19 vaccine candidates, dubbed TNX-1810, TNX-1820 and TNX-1830, all based on a horsepox vector platform and designed to elicit almost 100% T cell responses.

The parties will collaborate on development.

Financial terms remain confidential.

https://seekingalpha.com/news/3571302-tonix-pharma-secures-rights-to-three-covidminus-19-vaccine-candidates

Gilead confirms remdesivir approval in Japan for severe COVID-19

Under exceptional (emergency use) status, Japan’s Ministry of Health, Labor and Welfare has approved Gilead Sciences’ (GILD +0.4%) remdesivir, branded as Veklury, for the treatment of severely ill COVID-19 patients.
https://seekingalpha.com/news/3571333-gilead-confirms-remdesivir-approval-in-japan-for-severe-covidminus-19

Stericycle up 6% post Q1 results; withdraws FY20 guidance

Stericycle (SRCL +6.2%) reported revenue decline of 5.4% Y/Y to $785M, and organic increase of 2.4% Y/Y.

Revenue by services: Regulated Waste and Compliance $ 467.3M (-0.4% Y/Y); Secure Information Destruction $ 218.1M (-6% Y/Y); Communication and Related $ 33.6M (-45.1% Y/Y); and Manufacturing and Industrial $66M (-2.5% Y/Y).

Revenue by segments: North America $627.5M (-0.6% Y/Y); International $130.4M (-12.2% Y/Y); and Others $27.1M (-4 5.8Y/Y).

Q1 Gross margin improved by 70 bps to 36.5%.

Loss from operations expanded to $30.4M for the quarter, compared to $4.2M a year ago.

Cash flow from operations was $82.1M, compared to $36.2M a year ago.  Free Cash Flow was $42.5M, compared to an outflow of $29.9M a year ago.

Company witnessed business impact of the economic shut-down due to COVID-19 during March, primarily in their secure information destruction services.

Stericycle has withdrawn its FY20 financial guidance, due to uncertainties caused by COVID-19 pandemic.

Previously: Raymond James likes Amgen in premarket analyst action (March 30)

Previously: Stericycle EPS misses by $0.08, misses on revenue (May 7)

https://seekingalpha.com/news/3571385-stericycle-up-6-post-q1-results-withdraws-fy20-guidance

AmerisourceBergen EPS beats by $0.13, beats on revenue

AmerisourceBergen (NYSE:ABC): Q2 Non-GAAP EPS of $2.40 beats by $0.13; GAAP EPS of $4.64 beats by $3.60.

Revenue of $47.42B (+9.5% Y/Y) beats by $1.52B.

Press Release

https://seekingalpha.com/news/3570950-amerisourcebergen-eps-beats-0_13-beats-on-revenue

Endo EPS beats by $0.40, beats on revenue

Endo (NASDAQ:ENDP): Q1 Non-GAAP EPS of $0.95 beats by $0.40; GAAP EPS of $0.68 beats by $0.71.

Revenue of $820.41M (+13.9% Y/Y) beats by $106.79M.

Press Release

https://seekingalpha.com/news/3570914-endo-eps-beats-0_40-beats-on-revenue

Novo Nordisk reports Q1 results

Novo Nordisk (NYSE:NVO): Q1 GAAP EPS of DKK5.05.

Revenue of DKK33.88B (+15.7% Y/Y)

Shares +2.05% PM.

Press Release

https://seekingalpha.com/news/3570887-novo-nordisk-reports-q1-results

Becton, Dickinson EPS beats by $0.26, beats on revenue

Becton, Dickinson (NYSE:BDX): Q2 Non-GAAP EPS of $2.55 beats by $0.26; GAAP EPS of $0.53 misses by $1.93.

Revenue of $4.25B (+1.2% Y/Y) beats by $150M.

Press Release

https://seekingalpha.com/news/3570894-becton-dickinson-eps-beats-0_26-beats-on-revenue